Specific inhibition of tenascin-C with Cilostazol attenuates vascular proliferation in monocrotaline-induced pulmonary hypertension in rats

2015 Fiscal Year Final Research Report

• Project/Area Number: 24592057
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Thoracic surgery
• Research Institution: Mie University
• Principal Investigator: SHIMPO HIDETO 三重大学, 医学(系)研究科(研究院), 教授 (70179076)
• Co-Investigator(Renkei-kenkyūsha): SHIMAMOTO AKIRA 三重大学, 医学部附属病院, 講師 (90324524) ; MAESHIRO RYO 三重大学, 医学系研究科, 助教 (90647124) ; GOTO TAKEHIRO 三重大学, 医学部附属病院, 技術補佐員 (80774877) ; MATSUO ERI 三重大学, 医学系研究科, 特定事業技術補佐員 (40751665)
• Project Period (FY): 2012-04-01 – 2016-03-31
• Keywords: 肺高血圧 / 細胞外マトリックス / テネイシン

Outline of Final Research Achievements

Three weeks after monocrotaline administration to induced pulmonary hypertension (PH), daily treatment of phosphodiesterase inhibitor with Cilostazol significantly reduced mean pulmonary artery (PA) pressure and morphometric changes of PA. Tenascin-C expression were significantly reduced during all periods. We showed that Cilostazol ultimately prevented the progression of PH.

Free Research Field

心臓血管外科学